Attenuation of a vaccine strain of vaccinia virus via inactivation of interferon viroceptor

Journal of Gene Medicine

Volumn 8, Issue 7, 2006, Pages 814-823

  Dénes, Béla ^a,b   Gridley, Daila S ^a   Fodor, Nadja ^a   Takátsy, Zsuzsanna ^a   Timiryasova, Tatyana M ^a   Fodor, István ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTRAL VETERINARY INSTITUTE   (Hungary)

Author keywords

Imaging; Interferon; Lister; Mutant; Optical reporter; Vaccine; Vaccinia virus; Virulence

Indexed keywords

GAMMA INTERFERON RECEPTOR; GENE PRODUCT; RECOMBINANT VACCINE; VACCINIA VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL CULTURE; CELLULAR IMMUNITY; CONTROLLED STUDY; EPITHELIUM CELL; GENE INACTIVATION; GENE MUTATION; GLIA CELL; HUMORAL IMMUNITY; IMMUNOCOMPETENCE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MONITORING; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SURVIVAL RATE; VACCINIA VIRUS; VIRUS REPLICATION; VIRUS STRAIN; VIRUS VIRULENCE; WEIGHT GAIN;

ANIMALS; CELL LINE; CERCOPITHECUS AETHIOPS; GENE TRANSFER TECHNIQUES; GENES, REPORTER; IMMUNITY, CELLULAR; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PLASMIDS; RATS; RECEPTORS, INTERFERON; SAFETY; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRAL VACCINES; VIRULENCE;

MUS MUSCULUS; REPLICATION COMPETENT VIRUSES; VACCINIA VIRUS;

EID: 33746256606     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.907     Document Type: Article

References (48)

1. Finberg RW, Kurt-Jones EA. Viruses and Toll-like receptors. Microbes Infect 2004; 6: 1356-1360.
2. Goodbourn S, Didcock L, Randall RE. Interferons: cell signaling, immune modulation, antiviral response and virus countermeasures. J Gen Virol 2000; 81: 2341-2364.
3. Smith GL, Symons JA, Khanna A, Vanderplasschen A, Alcami A. Vaccinia virus immune evasion. Immunol Rev 1997; 159: 137-154.
4. Alcami A, Symons JA, Smith GL. The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN. J Virol 2000; 74: 11230-11239.
5. Johnston JB, McFadden G. Technical knockout: understanding poxvirus pathogenesis by selectively deleting viral immunomodulatory genes. Cell Microbiol 2004; 6: 695-705.
6. Symons JA, Alcami A, Smith GL. Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell 1995; 81: 551-560.
7. Symons JA, Tscharke DC, Price N, Smith GL. A study of the vaccinia virus interferon-gamma receptor and its contribution to virus virulence. J Gen Virol 2002; 83: 1953-1964.
8. Alcami A, Smith GL. Cytokine receptors encoded by poxviruses: a lesson in cytokine biology. Immunol Today 1995; 16: 474-478.
9. Alcami A, Smith GL. Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity. J Virol 1995; 69: 4633-4639.
10. Verardi PH, Jones LA, Aziz FH, Ahmad S, Yilma TD. Vaccinia virus vectors with an inactivated gamma interferon receptor homolog gene (B8R) are attenuated in vivo without a concomitant reduction in immunogenicity. J Virol 2001; 75: 11-18.
11. Chernos VI, Cheliapov NV, Antonova TP, et al. Verification of the safety, inoculability, reactogenicity and antigenic properties of a live recombinant smallpox-hepatitis B vaccine in an experiment in volunteers. Vopr Virusol (Moscow) 1990; 35: 132-135.
12. Wang Y, Wang G, O'Kane DJ, Szalay AA. The Renilla luciferase-modified GFP fusion protein is functional in transformed cells. In Bioluminescence and Chemiluminescence: Molecular Reporting with Photons, Hastings JW, Kricka LJ, Stanley PE (eds). John Wiley: Chichester, 1997; 419-422.
13. Timiryasova TM, Chen B, Fodor N, Fodor I. New methods for construction of recombinant vaccinia viruses using PUV-inactivated virus as a helper. Biotechnology 2001; 31: 534-540.
14. Goebel SJ, Johnson GP, Perkus ME, Davis SW, Winslow JP, Paoletti P. The complete DNA sequence of vaccinia virus. Virology 1990; 179: 247-266, 517-563.
15. Timiryasova T, Yu Y, Shabahang S, Fodor I, Szalay AA. Visualization of vaccinia virus infection using the Renilla luciferase-GFP fusion protein. In Proc 11th Int Symp Bioluminescence and Chemiluminescence 2000, Case JF, Herring PJ, Robison BH, Haddock SHD, Kricka LJ, Stanley PE (eds). John Wiley: Chichester, 2001; 457-460.
16. Timiryasova TM, Chen B, Haghighat P, Fodor I. Vaccinia virus-mediated expression of wild-type p53 suppresses glioma cell growth and induces apoptosis. Oncol Res 1999; 11: 133-144.
17. Gridley DS, Timiryasova TM, Miller GM, et al. Evaluation of TNF-alpha/ Bax gene therapy and radiation against C6 glioma xenografts. Technol Cancer Res Treat 2003; 2: 41-50.
18. Chacko MS, Ma X, Adamo ML. Double-stranded ribonucleic acid decreases c6 rat glioma cell proliferation in part by activating protein kinase R and decreasing insulin-like growth factor I levels. Endocrinology 2002; 143: 2144-2154.
19. John GR, Lee SC, Brosnan CF. Cytokines: powerful regulators of glial cell activation. Neuroscientist 2003; 9: 10-22.
20. Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968: national surveillance in the United States. N Engl J Med 1969; 281: 1201-1208.
21. Fenner F, Anderson DA, Arite I, Jezek Z, Ladnyi ID. Smallpox and Its Eradication. World Health Organization: Geneva, 1988.
22. Rosenthal SR, Merchlinsky M, Kleppinger C, Goldenthal KL. Developing new smallpox vaccines. Emerg Infect Dis 2001; 7: 920-926.
23. Timiryasova TM, Chen B, Fodor I. Replication-deficient vaccinia virus gene therapy vector: evaluation of exogenous gene expression mediated by PUV-inactivated virus in glioma cells. J Gene Med 2001; 3: 468-477.
24. Fodor I, Timiryasova T, Denes B, et al. Vaccinia virus mediated p53 gene therapy for bladder cancer in an orthotopic murine model. J Urol 2005; 173: 604-609.
25. McCart JA, Ward JM, Lee J, et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 2001; 61: 8751-8757.
26. Moss B. Genetically engineered poxvirus for recombinant gene expression, vaccination and safety. Proc Natl Acad Sci U S A 1996; 93: 11341-11348.
27. Puhlmann M, Brown CK, Gnant M, et al. Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Ther 2000; 7: 66-73.
28. Meyer H, Sutter G, Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 1991; 72: 1031-1038.
29. Flexner C, Hugin A, Moss B. Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression. Nature 1987; 330: 259-262.
30. Cantin E, Tanamachi B, Openshaw H, Mann J, Clarke K. Gamma interferon (IFN-gamma) receptor null-mutant mice are more susceptible to herpes simplex virus type 1 infection than IFN-gamma ligand null-mutant mice. J Virol 1999; 73: 5196-5200.
31. Huang S, Hendriks W, Althage A, et al. Immune response in mice that lack the interferon-gamma receptor. Science 1993; 259: 1742-1745.
32. Ramshaw IA, Ramsay AJ, Karupiah G, Rolph MS, Mahalingam S, Ruby JC. Cytokines and immunity to viral infections. Immunol Rev 1997; 159: 119-135.
33. Mossman K, Nation P, Macen J, Garbutt M, Lucas A, McFadden G. Myxoma virus M-T7, a secreted homolog of the interferon-gamma receptor, is a critical virulence factor for the development of myxomatosis in European rabbits. Virology 1996; 215: 17-30.
34. Boomker JM, Luttikhuizen DT, Veninga H, et al. The modulation of angiogenesis in the foreign body response by the poxviral protein M-T7. Biomaterials 2005; 26: 4874-4881.
35. Lalani AS, Graham K, Mossman K, et al. The purified myxoma virus gamma interferon receptor homolog M-T7 interacts with the heparin-binding domains of chemokines. J Virol 1997; 71: 4356-4363.
36. DiPerna G, Stack J, Bowie AG, et al. Poxvirus protein N1L targets the I-kappa B kinase complex, inhibits signaling to NF-kappa B by the tumor necrosis factor superfamily of receptors, and inhibits NF-kappa B and IRF3 signaling by toll-like receptors. J Biol Chem 2004; 279: 36570-36578.
37. Reading PC, Khanna A, Smith GL. Vaccinia virus CrmE encodes a soluble and cell surface tumor necrosis factor receptor that contributes to virus virulence. Virology 2002; 292: 285-298.
38. Beattie E, Denzler KL, Tartaglia J, et al. Reversal of the interferon-sensitive phenotype of a vaccinia virus lacking E3L by expression of the reovirus S4 gene. J Virol 1995; 69: 499-505.
39. Brandt T, Heck MC, Vijaysri S, et al. The N-terminal domain of the vaccinia virus E3L-protein is required for neurovirulence, but not induction of a protective immune response. Virology 2005; 333: 263-270.
40. Krausova VI, Kopilova-Sviridova TN, Timiryasova TM, Fodor I. Expression of the genes for glowworm luciferase in mammalian cells with the use of vaccinia virus vectors. Mol Genet Microb Virusol 1991; 2: 23-28.
41. Luker KE, Hutchens M, Schultz T, Pekosz A, Luker GD. Bioluminescence imaging of vaccinia virus: effects of interferon on viral replication and spread. Virology 2005; 341: 284-300.
42. Shinoda K, Xin KQ, Okuda K. A modified HIV challenge assay in mice by using luciferase-expressing vaccinia virus. Vaccine 2006; in press.
43. Gayle D, Ilyin SE, Miele ME, Plata-Salaman CR. Modulation of TNF-alpha mRNA production in rat C6 glioma cells by TNF-alpha, IL-1beta, IL-6, and IFN-alpha: in vitro analysis of cytokine-cytokine interactions. Brain Res Bull 1998; 47: 231-235.
44. Popko B, Corbin JG, Baerwald KD, Dupree J, Garcia AM. The effects of interferon-gamma on the central nervous system. Mol Neurobiol 1997; 14: 19-35.
45. Lee SB, Esteban M. The interferon-induced double-stranded RNA-activated human p68 protein kinase inhibits the replication of vaccinia virus. Virology 1993; 193: 1037-1041.
46. Suk K, Kim SY, Kim H. Essential role of caspase-11 in activation-induced cell death of rat astrocytes. J Neurochem 2002; 80: 230-238.
47. Harris N, Buller RM, Karupiah G. Gamma interferon-induced, nitric oxide-mediated inhibition of vaccinia virus replication. J Virol 1995; 69: 910-915.
48. Nguyen VT, Benveniste EN. Critical role of tumor necrosis factor-alpha and NF-kappa B in interferon-gamma-induced CD40 expression in microglia/ macrophages. J Biol Chem 2002; 277: 13796-13803.